Lipitor vs Repatha: Switching Between Atorvastatin and Evolocumab

Is a switch from Lipitor to Repatha a swap or an add-on?

Lipitor (atorvastatin calcium) is an oral HMG-CoA reductase inhibitor approved on 17 December 1996 for lowering LDL-C and reducing cardiovascular risk [1][4]. Repatha (evolocumab) is a PCSK9 antibody approved on 27 August 2015, given by subcutaneous injection, and labeled to reduce the risk of major adverse cardiovascular events in adults at increased risk and to lower LDL-C as an adjunct to diet and exercise in adults with hypercholesterolemia and in adults and children 10 years and older with heterozygous or homozygous familial hypercholesterolemia [2][5].

The cardiovascular outcome evidence for evolocumab was built on top of statin therapy. FOURIER randomized 27,564 adults with established atherosclerotic cardiovascular disease and LDL-C of 70 mg/dL or higher who were receiving a statin; 69% were on a high-intensity statin, 81% had a prior myocardial infarction and 25% were women [3]. The 2026 VESALIUS-CV trial tested evolocumab 140 mg every 2 weeks against placebo in 12,257 people with atherosclerosis or diabetes and no previous myocardial infarction or stroke [6].

Evolocumab's labeled indications are not conditioned on statin intolerance [2].

How the two drugs lower LDL-C differently

Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate; in animal models that lowers hepatic cholesterol synthesis, raises the number of hepatic LDL receptors, and reduces LDL production and LDL particle number [1]. In pooled 6-week dose-response data in primary hyperlipidemia, LDL-C fell 39% on 10 mg, 43% on 20 mg, 50% on 40 mg and 60% on 80 mg, against a 4% rise on placebo [1].

Evolocumab binds PCSK9, a protein that normally binds the LDL receptor on liver cells and promotes its degradation; blocking that binding leaves more LDL receptors available to clear LDL from the blood [2]. In LAPLACE-2, 1,896 patients with hypercholesterolemia who were already taking atorvastatin, rosuvastatin or simvastatin received evolocumab or a comparator for 12 weeks; the LDL-C difference from placebo was -71% with 140 mg every 2 weeks and -63% with 420 mg monthly, and from ezetimibe 10 mg it was -45% and -41% [2].

The atorvastatin percentages come from patients not on a PCSK9 antibody, and the evolocumab percentages come from patients on a background statin, so the two sets of numbers describe different situations [1][2].

What happens to the atorvastatin when Repatha is added

The Repatha label has no drug interactions section. It reports about 20% lower Cmax and AUC of evolocumab in adults on a high-intensity statin, which the label calls not clinically meaningful, and states that age, sex, race and creatinine clearance did not affect evolocumab pharmacokinetics [2]. Evolocumab is eliminated by target binding and proteolysis [2].

Atorvastatin is a CYP3A4 substrate. The Lipitor label reports that clarithromycin 500 mg twice daily raised its AUC 4.54-fold and itraconazole 200 mg daily 3.32-fold, and says not to exceed 20 mg of atorvastatin with either. It calls concomitant cyclosporine and gemfibrozil not recommended, and says to avoid large quantities of grapefruit juice, more than 1.2 liters daily [1].

Switching back from Repatha to atorvastatin

Evolocumab is absorbed slowly: median peak concentration 3 to 4 days after a subcutaneous dose, absolute bioavailability about 72%, effective half-life 11 to 17 days, and trough levels that approach steady state by 12 weeks [2]. Atorvastatin peaks within 1 to 2 hours, with a half-life of about 14 hours and 20 to 30 hours of inhibitory activity [1].

Both labels give the same first checkpoint. Lipitor's label says to assess LDL-C as early as 4 weeks after starting and adjust the dose if necessary [1]. Repatha's label says the LDL-lowering effect may be measured as early as 4 weeks, and that with the once-monthly regimen the measurement is taken just before the next dose [2].

One detail matters if atorvastatin was stopped for muscle symptoms. The Lipitor label describes immune-mediated necrotizing myopathy, a rare autoimmune myopathy with proximal muscle weakness, a creatine kinase that stays elevated despite stopping the statin, positive anti-HMG-CoA reductase antibodies and improvement with immunosuppressive agents; it has recurred when the same or a different statin was given [1].

Doses, timing and missed doses

Atorvastatin (Lipitor label):

• Starting dose 10 or 20 mg once daily, range 10 to 80 mg; 40 mg may be used to start when LDL-C needs to fall by more than 45% [1]
• Any time of day, with or without food; food lowers Cmax about 25% and AUC about 9%, and evening dosing lowers Cmax and AUC about 30%, but LDL-C reduction is the same either way [1]
• A missed dose is skipped and the next scheduled dose is taken [1]

Evolocumab (Repatha label):

• 140 mg every 2 weeks or 420 mg once monthly for adults at increased cardiovascular risk or with hypercholesterolemia, and for heterozygous familial hypercholesterolemia; the 420 mg dose is three 140 mg injections given within 30 minutes [2]
• Homozygous familial hypercholesterolemia: starts at 420 mg monthly, and the dose can go to 420 mg every 2 weeks if the response is not clinically meaningful by 12 weeks; patients on lipid apheresis may start 420 mg every 2 weeks and dose after the session [2]
• Missed dose: if it is within 7 days of the missed date, give it and resume the original schedule. If it is more than 7 days late, wait for the next scheduled dose on the every-2-week schedule; on the monthly regimen, give the dose and start a new schedule [2]
• Storage at 2 to 8 C in the carton, 30 minutes to reach room temperature before injecting, and subcutaneous injection into the abdomen, thigh or upper arm; some needle covers contain dry natural rubber [2]

Safety differences that matter when switching

Atorvastatin's label lists myopathy and rhabdomyolysis, with risk factors of age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher dose, plus rare immune-mediated necrotizing myopathy [1]. Persistent transaminase rises above 3 times the upper limit of normal occurred in about 0.7% of patients overall, and in 0.2%, 0.2%, 0.6% and 2.3% at 10, 20, 40 and 80 mg [1]. In 17 placebo-controlled trials, myalgia was 3.5% versus 3.1% on placebo and nasopharyngitis 8.3% versus 8.2% [1]. In TNT, 80 mg produced more serious adverse reactions (1.8% vs 1.4%) and more discontinuations for adverse reactions (9.9% vs 8.1%) than 10 mg over a median 4.9 years [1]. A post-hoc analysis of SPARCL found hemorrhagic stroke in 2.3% of patients on 80 mg versus 1.4% on placebo (HR 1.68, 95% CI 1.09-2.59) among people who had a stroke or TIA in the previous 6 months [1][7].

Evolocumab has no boxed warning. It is contraindicated after a serious hypersensitivity reaction to it, and serious reactions including angioedema have occurred; the label says to stop treatment and treat if serious hypersensitivity symptoms appear [2]. In eight pooled controlled trials, injection site reactions were 3.2% versus 3.0% on placebo and hypersensitivity reactions 5.1% versus 4.7% [2]. In a 52-week placebo-controlled trial, myalgia was 4.0% versus 3.0% and discontinuation because of myalgia 0.3% versus 0% [2]. Binding antibodies developed in 0.3% of adults (48 of 17,992), none neutralizing [2]. In FOURIER, new-onset diabetes among people without diabetes at baseline was 8.1% on evolocumab versus 7.7% on placebo [2]. The cognitive substudy EBBINGHAUS found evolocumab non-inferior to placebo on executive function and other cognitive domains over a median 19 months [8][2].

These muscle-pain rates come from different trials in different populations, and the Lipitor label states that adverse reaction rates from separate trials cannot be directly compared [1].

What each drug has shown in outcome trials

Atorvastatin: ASCOT-LLA randomized 10,305 hypertensive patients to 10 mg or placebo, stopped at a median 3.3 years, with non-fatal myocardial infarction plus fatal CHD in 100 versus 154 events (HR 0.64) [9]. CARDS randomized 2,838 people with type 2 diabetes to 10 mg or placebo and found major cardiovascular events in 83 versus 127, a 37% rate reduction, with stroke reduced 48% [10]. TNT randomized 10,001 patients with stable CHD to 80 mg or 10 mg; major cardiovascular events occurred in 8.7% versus 10.9% (HR 0.78), with no difference in overall mortality [11]. SPARCL randomized 4,731 people after stroke or TIA to 80 mg or placebo; fatal or non-fatal stroke occurred in 11.2% versus 13.1% (HR 0.84) [7].

Evolocumab: FOURIER compared evolocumab with placebo on background statin therapy and found the primary composite in 9.8% versus 11.3% (HR 0.85) and cardiovascular death, myocardial infarction or stroke in 5.9% versus 7.4% (HR 0.80), but cardiovascular death (HR 1.05) and all-cause death (HR 1.04) did not differ [3][2]. VESALIUS-CV compared evolocumab with placebo in people without a prior myocardial infarction or stroke; 3-point MACE occurred in 6.2% versus 8.0% at 5 years (HR 0.75) [6]. The Repatha label reports all-cause death HR 0.80 and a CHD death hazard ratio of 0.90 that did not meet statistical significance [2].